[
  {
    "ts": null,
    "headline": "Is Pfizer Stock an Underrated Healthcare Investment Play?",
    "summary": "Pfizer is playing catch-up in the GLP-1 drug space, but the drugmaker has a long history of success.",
    "url": "https://finnhub.io/api/news?id=867d50ec02f9eeec157b977fa6208664d76f6e23196c030d38eda1889197a8e4",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1771622400,
      "headline": "Is Pfizer Stock an Underrated Healthcare Investment Play?",
      "id": 139163792,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Pfizer is playing catch-up in the GLP-1 drug space, but the drugmaker has a long history of success.",
      "url": "https://finnhub.io/api/news?id=867d50ec02f9eeec157b977fa6208664d76f6e23196c030d38eda1889197a8e4"
    }
  },
  {
    "ts": null,
    "headline": "Barclays Initiates Coverage of Pfizer (PFE) with Underweight Recommendation",
    "summary": "Barclays Initiates Coverage of Pfizer (PFE) with Underweight Recommendation",
    "url": "https://finnhub.io/api/news?id=75b826e76a130d9bbe07997fb50be622da4f249e55f09f2b0da9608911588643",
    "source": "Fintel",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1771617857,
      "headline": "Barclays Initiates Coverage of Pfizer (PFE) with Underweight Recommendation",
      "id": 139163480,
      "image": "",
      "related": "PFE",
      "source": "Fintel",
      "summary": "",
      "url": "https://finnhub.io/api/news?id=75b826e76a130d9bbe07997fb50be622da4f249e55f09f2b0da9608911588643"
    }
  },
  {
    "ts": null,
    "headline": "Explore the S&P500 index on Friday and find out which stocks are the most active in today's session.",
    "summary": "Explore the S&P500 index on Friday and find out which stocks are the most active in today's session. Stay updated with the stocks that are capturing market interest.",
    "url": "https://finnhub.io/api/news?id=53cb9da7094813f06992682f4e42e158d225ceae4f04e8b9abd261a611a4ddd2",
    "source": "ChartMill",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1771614306,
      "headline": "Explore the S&P500 index on Friday and find out which stocks are the most active in today's session.",
      "id": 139163011,
      "image": "https://www.chartmill.com/images/uploads/CM_Most_Active_Stocks_Small_free_fec0650b7f.webp",
      "related": "PFE",
      "source": "ChartMill",
      "summary": "Explore the S&P500 index on Friday and find out which stocks are the most active in today's session. Stay updated with the stocks that are capturing market interest.",
      "url": "https://finnhub.io/api/news?id=53cb9da7094813f06992682f4e42e158d225ceae4f04e8b9abd261a611a4ddd2"
    }
  },
  {
    "ts": null,
    "headline": "AstraZeneca vs. Pfizer: Which Pharma Giant Has the Edge in 2026?",
    "summary": "AZN's stronger growth outlook and 2030 revenue target may outshine PFE's yield and cheaper valuation.",
    "url": "https://finnhub.io/api/news?id=5fb5d56ec785de479f27bee86320d329962e67ab43172d951599d10154396dae",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1771602360,
      "headline": "AstraZeneca vs. Pfizer: Which Pharma Giant Has the Edge in 2026?",
      "id": 139162623,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "AZN's stronger growth outlook and 2030 revenue target may outshine PFE's yield and cheaper valuation.",
      "url": "https://finnhub.io/api/news?id=5fb5d56ec785de479f27bee86320d329962e67ab43172d951599d10154396dae"
    }
  },
  {
    "ts": null,
    "headline": "Barclays launches U.S. biopharma coverage with four preferred picks",
    "summary": "Investing.com -- Barclays launched coverage of U.S. large-cap biopharmaceutical companies, arguing the sector could regain investor attention in an uncertain macro backdrop, while naming Eli Lilly (NYSE:LLY), Merck (NYSE:MRK), Bristol-Myers Squibb (NYSE:BMY) and AbbVie Inc (NYSE:ABBV) as its top picks.",
    "url": "https://finnhub.io/api/news?id=24defe4374fd77db8c0683e041cc1dc376df6732125794a437ba7de5060bb531",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1771592903,
      "headline": "Barclays launches U.S. biopharma coverage with four preferred picks",
      "id": 139159098,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Investing.com -- Barclays launched coverage of U.S. large-cap biopharmaceutical companies, arguing the sector could regain investor attention in an uncertain macro backdrop, while naming Eli Lilly (NYSE:LLY), Merck (NYSE:MRK), Bristol-Myers Squibb (NYSE:BMY) and AbbVie Inc (NYSE:ABBV) as its top picks.",
      "url": "https://finnhub.io/api/news?id=24defe4374fd77db8c0683e041cc1dc376df6732125794a437ba7de5060bb531"
    }
  },
  {
    "ts": null,
    "headline": "Nicotine Gum Market Analysis Report 2026-2035: A $2.55 Billion Market by 2030 with Pfizer, GlaxoSmithKline, Haleon, Perrigo Co, and Johnson & Johnson Leading",
    "summary": "The nicotine gum market presents opportunities through rising anti-smoking campaigns, demand for convenient cessation solutions, flavored variants, and online channels. Innovations like lozenges enhance market position. Asia-Pacific shows rapid growth potential, aided by increasing tobacco prices and regulatory support. Nicotine Gum Market Nicotine Gum Market Dublin, Feb. 20, 2026 (GLOBE NEWSWIRE) -- The \"Nicotine Gum Market Report 2026\" has been added to ResearchAndMarkets.com's offering. The n",
    "url": "https://finnhub.io/api/news?id=2ba4aca969b52cae9d6ad8c9b59afd8cea78bf6df7fd0b8ab8fd14e28a4a0ee9",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1771583640,
      "headline": "Nicotine Gum Market Analysis Report 2026-2035: A $2.55 Billion Market by 2030 with Pfizer, GlaxoSmithKline, Haleon, Perrigo Co, and Johnson & Johnson Leading",
      "id": 139158116,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "The nicotine gum market presents opportunities through rising anti-smoking campaigns, demand for convenient cessation solutions, flavored variants, and online channels. Innovations like lozenges enhance market position. Asia-Pacific shows rapid growth potential, aided by increasing tobacco prices and regulatory support. Nicotine Gum Market Nicotine Gum Market Dublin, Feb. 20, 2026 (GLOBE NEWSWIRE) -- The \"Nicotine Gum Market Report 2026\" has been added to ResearchAndMarkets.com's offering. The n",
      "url": "https://finnhub.io/api/news?id=2ba4aca969b52cae9d6ad8c9b59afd8cea78bf6df7fd0b8ab8fd14e28a4a0ee9"
    }
  },
  {
    "ts": null,
    "headline": "Tobacco Alternative Gums Analysis Report 2026-2035: A $4.25 Billion Market by 2030 with CVS Health, The Kroger Co., Walgreens Boots Alliance, along with Pfizer, Johnson & Johnson Leading",
    "summary": "The tobacco alternative gums market presents key opportunities due to rising awareness of smoking risks, innovative nicotine-free products, e-commerce expansion, and growing demand for discreet alternatives. Strategic partnerships, domestic manufacturing, and a supportive regulatory environment further enhance market potential. Tobacco Alternative Gums Market Tobacco Alternative Gums Market Dublin, Feb. 20, 2026 (GLOBE NEWSWIRE) -- The \"Tobacco Alternative Gums Market Report 2026\" has been added",
    "url": "https://finnhub.io/api/news?id=b5c2deecaf3be9df2dda52832f7e593127399c8a51f15d2006b4a5780f281aad",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1771582860,
      "headline": "Tobacco Alternative Gums Analysis Report 2026-2035: A $4.25 Billion Market by 2030 with CVS Health, The Kroger Co., Walgreens Boots Alliance, along with Pfizer, Johnson & Johnson Leading",
      "id": 139158117,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "The tobacco alternative gums market presents key opportunities due to rising awareness of smoking risks, innovative nicotine-free products, e-commerce expansion, and growing demand for discreet alternatives. Strategic partnerships, domestic manufacturing, and a supportive regulatory environment further enhance market potential. Tobacco Alternative Gums Market Tobacco Alternative Gums Market Dublin, Feb. 20, 2026 (GLOBE NEWSWIRE) -- The \"Tobacco Alternative Gums Market Report 2026\" has been added",
      "url": "https://finnhub.io/api/news?id=b5c2deecaf3be9df2dda52832f7e593127399c8a51f15d2006b4a5780f281aad"
    }
  },
  {
    "ts": null,
    "headline": "Pfizer Inc (PFE) Announces Positive Results from BREAKWATER Trial",
    "summary": "​Pfizer Inc. (NYSE:PFE) is among the Best Affordable Stocks Under $40 to Buy. On February 17, Pfizer Inc. (NYSE:PFE) announced positive results from its key BREAKWATER trial, which is testing BRAFTOVI in combination with cetuximab and FOLFIRI in patients with metastatic colorectal cancer. Management noted that the combination showed significant PFS improvement and better overall […]",
    "url": "https://finnhub.io/api/news?id=c195532ab12698fcca83f5969c41163f40ed105b0e44ea7f5b0652c2e0b34463",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1771576484,
      "headline": "Pfizer Inc (PFE) Announces Positive Results from BREAKWATER Trial",
      "id": 139157235,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "​Pfizer Inc. (NYSE:PFE) is among the Best Affordable Stocks Under $40 to Buy. On February 17, Pfizer Inc. (NYSE:PFE) announced positive results from its key BREAKWATER trial, which is testing BRAFTOVI in combination with cetuximab and FOLFIRI in patients with metastatic colorectal cancer. Management noted that the combination showed significant PFS improvement and better overall […]",
      "url": "https://finnhub.io/api/news?id=c195532ab12698fcca83f5969c41163f40ed105b0e44ea7f5b0652c2e0b34463"
    }
  },
  {
    "ts": null,
    "headline": "Is Pfizer Stock the Only Big Pharma Name I'd Buy and Hold Through Any Market Crash?",
    "summary": "New products are already generating growth.",
    "url": "https://finnhub.io/api/news?id=a63fcc99c3d3639e9e8b3ed0fa1fde98a9d84e9451411ab5b5f2af58210c478c",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1771574700,
      "headline": "Is Pfizer Stock the Only Big Pharma Name I'd Buy and Hold Through Any Market Crash?",
      "id": 139157236,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "New products are already generating growth.",
      "url": "https://finnhub.io/api/news?id=a63fcc99c3d3639e9e8b3ed0fa1fde98a9d84e9451411ab5b5f2af58210c478c"
    }
  }
]